FOLH1 and prostate carcinoma: PSMA, a transmembrane glycoprotein, is the most successful molecular target for imaging and therapy of clinically significant prostate cancer.28It is overexpressed in prostate cancer compared to normal prostate tissue or benign prostate disorders, and its level of expression is proportional to the level of disease aggressiveness.29, 30Several small-molecule ligands targeting prostate cancer-expressed PSMA have been labeled with PET radionuclides, such as gallium-68 (68Ga) and fluorine-18 (18F), for PET imaging of prostate cancer in different clinical settings.